Outcome of Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients
Recruitment status was Active, not recruiting
This observational study will based on the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) and the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) which since 2009 are merged into The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART).
The aim of this study is to investigate the impact of different antithrombotic treatment options (treatment duration, type of treatment and combination of treatments) in Acute Coronary Syndrome (ACS) patients on outcomes such as recurrent ischemic events and mortality.
Acute Coronary Syndrome
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||A Retrospective Epidemiological Study to Investigate Outcome and Mortality With Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients|
- number of patients with adverse events in patient groups with different antithrombotic treatment strategies [ Time Frame: up to 5 years and 6 months ] [ Designated as safety issue: No ]adverse events such as: mortality, re-infarction, revascularization, ischemic- and non-ischemic stroke and bleeding
|Study Start Date:||January 2006|
|dual antiplatelet treatment 12 months after ACS event|
|dual antiplatelet treatment 6 months after ACS event|
|dual antiplatelet treatment 3 months after ACS event|
|Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University|
|Uppsala, Uppsala County, Sweden, 75237|
|Principal Investigator:||Stefan James, MD, PhD||Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology|